Jayne B. Hart - 28 Feb 2022 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Chief People Officer
Signature
By: Nathan A. Smith For: Jayne B. Hart
Issuer symbol
MYGN
Transactions as of
28 Feb 2022
Net transactions value
-$10,710
Form type
4
Filing time
01 Mar 2022, 15:55:02 UTC
Previous filing
18 Feb 2022
Next filing
23 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Options Exercise $167,860 +7,000 +4.2% $23.98 172,878 28 Feb 2022 Direct F1, F2
transaction MYGN Common Stock Sale $175,000 -7,000 -4% $25.00 165,878 28 Feb 2022 Direct F1
transaction MYGN Common Stock Options Exercise $83,930 +3,500 +2.1% $23.98 169,378 28 Feb 2022 Direct F1, F2
transaction MYGN Common Stock Sale $87,500 -3,500 -2.1% $25.00 165,878 28 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYGN Incentive Stock Option (right to buy) Options Exercise $0 -3,500 -100% $0.000000* 0 28 Feb 2022 Common Stock 3,500 $23.98 Direct F1, F3
transaction MYGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -7,000 -100% $0.000000* 0 28 Feb 2022 Common Stock 7,000 $23.98 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 Represents shares of common stock received upon exercise of a stock option award.
F3 The shares subject to this option are fully vested and exercisable.